Add BrightSurf on Google Email

Most academic institutions unprepared to meet new HHS clinical trial reporting regulations

A recent study found that many academic institutions in the US are unprepared to comply with stricter requirements for clinical trial registration and reporting. The institutions face challenges in allocating staff time and resources to meet these new regulations. As a result, some organizations have not implemented policies to punish ...

Culprit vessel-only strategy has lower mortality rates compared to routine MVI

A contemporary real-world analysis of culprit vessel-only intervention (CVI) versus multivessel intervention (MVI) in patients with acute myocardial infarction (AMI) and cardiogenic shock (CS) found lower mortality rates for CVI. The study, presented at the Society for Cardiovascular Angiography and Interventions 2018 Scientific Sessio...

SourceSociety for Cardiovascular Angiography and Interventions·JournalCatheterization and Cardiovascular Interventions·DateApr 27, 2018

New results from preserve clinical trial include data on patients who underwent PCI

The Preserve clinical trial has revealed significant benefits of oral acetylcysteine and sodium bicarbonate in reducing cardiovascular complications. Researchers analyzed data from a large cohort of high-risk patients who underwent PCI, demonstrating the efficacy of this treatment approach.

SourceSociety for Cardiovascular Angiography and Interventions·JournalCatheterization and Cardiovascular Interventions·DateApr 26, 2018

New clinical trial shows second generation drug-eluting stents are safe and effective

The PERSPECTIVE trial presents a comprehensive review of the safety, efficacy, and durability of Zotarolimus-Eluting Stents in treating chronic total occlusion. Treatment with second-generation drug-eluting stents resulted in lower occurrence of adverse events compared to previous DES trials.

SourceSociety for Cardiovascular Angiography and Interventions·JournalCatheterization and Cardiovascular Interventions·DateApr 26, 2018

SCAI releases consensus guidelines for PVD device selection

The Society for Cardiovascular Angiography and Interventions (SCAI) has released new guidelines for selecting specific categories of devices in endovascular therapy. The guidelines provide device-focused recommendations based on a review of comparative effectiveness data, including safety and efficacy of femoral-popliteal devices.

SourceSociety for Cardiovascular Angiography and Interventions·JournalCatheterization and Cardiovascular Interventions·DateApr 25, 2018

Interventions to decrease cardiovascular disease are not one-size-fits-all

A recent study published in Annals of Family Medicine found that interventions to decrease cardiovascular disease are not one-size-fits-all. Community-based approaches, such as the Boot Camp Translation method, can elicit unique contextual messages and materials that may be more effective for specific primary care practices.

SourceAmerican Academy of Family Physicians·JournalThe Annals of Family Medicine·DateApr 9, 2018

What is the best way to treat infected hip replacements?

A recent study has found that treating an infected hip replacement in a single stage procedure may be as effective or better than the widely used two-stage procedure. The one-stage revision strategy is shown to have advantages for patients, including shorter hospital stays and reduced functional impairment. However, further research is...

SourceUniversity of Bristol·JournalEuropean Journal of Epidemiology·DateApr 5, 2018

New cardiac pump device improves long-term outcomes for heart failure patients

The MOMENTUM 3 clinical trial found that advanced heart-failure patients who received a centrifugal-flow circulatory pump had significantly lower rates of pump-related blood clots and stroke compared to those receiving an axial flow pump. Patients who received the centrifugal-flow pump also had fewer re-operations due to device malfunc...

SourceBrigham and Women's Hospital·JournalNew England Journal of Medicine·DateMar 11, 2018

'Fighting my cancer as much as possible': Why many patients join phase 1 clinical trials

Research at the TAT International Congress 2018 found that patients participate in phase 1 clinical trials for access to innovative cancer treatments, including targeted therapies and immunotherapy. The studies suggest that this increased participation is driven by a growing awareness of treatment options beyond traditional chemotherapy.

SourceEuropean Society for Medical Oncology·JournalAnnals of Oncology·DateMar 5, 2018

US hospitals testing experimental therapies to prevent two common bacterial infections

The National Institute of Allergy and Infectious Diseases is supporting clinical trials testing monoclonal antibodies as preventive therapies for antibiotic-resistant infections. The trials aim to prevent pneumonia caused by Pseudomonas aeruginosa and Staphylococcus aureus, two bacteria posing a significant threat to human health.

Is cupping therapy effective among athletes?

A new systematic review of eleven clinical trials involving nearly 500 participants found that cupping therapy has a high risk of bias and inconsistent results. The authors concluded that no conclusive recommendations for or against the use of cupping in sports performance can be made until further trials are carried out.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalThe Journal of Alternative and Complementary Medicine·DateFeb 13, 2018

Are women really under-represented in clinical trials?

A recent review of US Food and Drug Administration registration data reveals that the proportion of women participating in clinical trials gradually increases from phase 1 to phase 2/3 trials. The analysis of 38 drugs with over 185,000 trial participants shows no systemic significant under-representation of women.

SourceWiley·JournalBritish Journal of Clinical Pharmacology·DateJan 11, 2018